Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on September 18, 2018. The Company is an emerging growth company developing gemcabene for dyslipidemia indications. The report details a strategic workforce reduction approved by the Board to conserve cash following a request by the FDA for additional pre-clinical data to schedule an End of Phase 2 meeting.
Key Financial Metrics and Restructuring Costs
The filing does not provide revenue, profit, or general cash flow metrics for the period. It focuses exclusively on estimated costs associated with exit activities:
- Total Estimated Severance Charges: Approximately $1.4 million.
- Cash Severance Payments: Approximately $0.5 million (one-time).
- Non-Cash Charges: Approximately $0.9 million (accelerated vesting of stock options).
- Health Insurance Coverage: $26,400.
- Workforce Impact: Reduction of 5 employees, representing approximately 33% of the total workforce.
Material Changes and Executive Departures
The workforce reduction resulted in the departure of two key executives, both leaving in good standing:
- Jeffrey S. Mathiesen (CFO): Departed effective September 21, 2018. Separation package includes a $167,500 lump sum, accelerated vesting of options through August 4, 2019, and 12 months of health insurance. He will provide consulting services for eight months.
- Lee Golden (CMO): Departed effective September 21, 2018. Separation package includes a $182,500 lump sum and accelerated vesting of options through October 5, 2019.
- Leadership Change: Dr. Steven Gullans (President and CEO) was designated as the new Principal Financial Officer and Principal Accounting Officer with no change to his existing compensation.
Outlook, Risks, and Contingencies
Management expects the majority of cash payments for restructuring to occur in the fourth quarter of 2018, with health insurance payments continuing through the third quarter of 2019. The filing includes significant forward-looking statements with the following risks:
- Actual restructuring costs may differ materially from estimates due to assumptions and unforeseen events.
- The workforce reduction may adversely impact the Company's drug development activities.
- The Company disclaims any obligation to update forward-looking statements except as required by law.
Investor Verification Checklist
- Verify the actual cash burn rate and remaining liquidity in the upcoming 10-Q filing for the period ending September 30, 2018.
- Confirm the final amount of non-cash charges related to accelerated stock option vesting in the financial statements.
- Monitor the timeline for the FDA End of Phase 2 meeting for gemcabene given the reduction in medical and financial leadership.
- Review the full text of the Separation and Release Agreements for Mathiesen and Golden when filed as exhibits to the 10-Q.